Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Small Cell Lung Carcinoma 16Breast Neoplasms 13Sarcoma 10Carcinoma, Hepatocellular 8Esophageal Squamous Cell Carcinoma 7Lung Neoplasms 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Carcinoma 5Stomach Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Thyroid Neoplasms 3Recurrence 3Paraganglioma 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × anlotinib × Clear all
NCT03736837 2021-03-15

ALTER-L004

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04566952 2020-10-30

ANLOLA

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
68 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT01878448 2019-05-22

ALTN/STS

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
166 enrolled
Tumor-Agnostic

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
58 enrolled
Tumor-Agnostic

Neoplasms

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0302)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
117 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡